Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study

Objective To characterise disease control and remission in patients with SLE receiving belimumab for up to 12 months in the real world.Methods This post hoc analysis (GSK Study 213502) used data from the US evaluation Of use of Belimumab in clinical practice SEttings (OBSErve) study (GSK Study 11729...

Full description

Bibliographic Details
Main Authors: Holly Quasny, Anna Richards, Jacob N Hunnicutt, Jolyon Fairburn-Beech, Mary Elizabeth Georgiou, Yun Irene Gregan, Deven Chauhan
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/9/1/e000710.full

Internet

https://lupus.bmj.com/content/9/1/e000710.full

Similar Items